Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Judith A. Biggs"'
Autor:
C. Thomas Nugent, Eric G. Pamer, Kristi Marquardt, Linda A. Sherman, Judith A. Biggs, Michael A. Lyman
Publikováno v:
The Journal of Immunology. 174:2563-2572
A major challenge in tumor immunology is how best to activate the relatively low avidity self-specific and tumor-specific T cells that are available in the self-tolerant repertoire. To address this issue, we produced a TCR transgenic mouse expressing
Autor:
Valérie C. Asensio, Pankaj Tailor, Iain L. Campbell, Judith A. Biggs, Anwar Murtaza, C. Thomas Nugent, Linda A. Sherman
Publikováno v:
International Immunology. 13:1085-1093
To further define the molecular basis of tolerance to a peripherally expressed antigen we have correlated differences in functional capacity with biochemical events in hemagglutinin (HA)-specific cytotoxic T lymphocyte (CTL) clones derived either fro
Autor:
Huub T. C. Kreuwel, Judith A. Biggs, David Lo, Eric G. Pamer, Linda A. Sherman, Ingrid M. Pilip
Publikováno v:
The Journal of Immunology. 167:1112-1117
Nonobese diabetic (NOD) mice develop spontaneous autoimmune diabetes that involves participation of both CD4+ and CD8+ T cells. Previous studies have demonstrated spontaneous reactivity to self-Ags within the CD4+ T cell compartment in this strain. W
Autor:
Judith A. Biggs, Javier Hernandez, Colleen Labadie, Joseph Lustgarten, Linda A. Sherman, Matthias Theobald
Publikováno v:
The Journal of Experimental Medicine
Elevated levels of the p53 protein occur in ∼50% of human malignancies, which makes it an excellent target for a broad-spectrum T cell immunotherapy of cancer. A major barrier to the design of p53-specific immunotherapeutics and vaccines, however,
Publikováno v:
Europe PubMed Central
A major barrier to the design of immunotherapeutics and vaccines for cancer is the idiosyncratic nature of many tumor antigens and the possibility that T cells may be tolerant of broadly distributed antigens. We have devised an experimental strategy
Publikováno v:
The Journal of Experimental Medicine
Mutations within the class I major histocompatibility complex (MHC) molecule that affect a peptide binding can result in strong allogeneic responses. It is believed this reflects, in part, binding of a different set of endogenous peptides by each MHC
Publikováno v:
The FASEB Journal. 22
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 172(11)
In this report, we address whether a growing tumor provides sufficient inflammatory signals to promote activation, clonal expansion, and acquisition of effector functions by naive tumor-specific CD8+ T lymphocytes. CD8+ T lymphocytes obtained from he
Autor:
Robert F. Dick, Jeffrey A. Bluestone, Judith A. Biggs, Suschmitta Chattopadhyay, Linda A. Sherman
Publikováno v:
Proceedings of the National Academy of Sciences. 90:6949-6951
Molecules encoded by a single major histocompatibility complex class I gene can associate with any one of a large number of peptide ligands. T-cell receptors have the capacity to discriminate among these peptide-class I complexes and in many cases bi
Autor:
Judith A. Biggs, Huub T. C. Kreuwel, A Murtaza, Linda A. Sherman, David J. Morgan, Alice Ko, F J Hernandez, C T Nugent
Publikováno v:
Immunologic research. 21(2-3)
T cell recognition of self-major histocompatibility complex-peptide complexes dictates the composition of the T cell receptor repertoire. Research projects in our laboratory deal with the mechanisms that regulate the composition of the repertoire spe